مؤتمر
A prospective phase 2 study to assess minimal residual disease ixazomib, lenalidomide, dexamethasone (IRD) treatment for newly diagnosed transplant eligible multiple myeloma patients /
| العنوان: | A prospective phase 2 study to assess minimal residual disease ixazomib, lenalidomide, dexamethasone (IRD) treatment for newly diagnosed transplant eligible multiple myeloma patients / |
|---|---|
| المؤلفون: | Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Pečeliūnas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Axelsson, Per, Svensson, Ronald, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzevičienė, Rėda, Hoyseter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth |
| المصدر: | HemaSphere: 28th Congress of the European Hematology Association EHA2023, June 8 - 15, Frankfurt, 2023 : abstract book., Philadelphia : Wolters Kluwer Health, Inc., 2023, vol. 7, suppl. S3, poster no. P898, p. 1693-1694. ; eISSN 2572-9241 |
| سنة النشر: | 2023 |
| المجموعة: | Vilnius University Virtual Library (VU VL) / Vilniaus universitetas virtuali biblioteka |
| مصطلحات موضوعية: | Multiple myeloma, Minimal residual disease (MRD), High risk |
| نوع الوثيقة: | conference object |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://epublications.vu.lt/object/elaba:190751850/190751850.pdfTest; https://repository.vu.lt/VU:ELABAPDB190751850&prefLang=en_USTest |
| الإتاحة: | https://doi.org/10.1097/01.HS9.0000970496.55340.69Test https://repository.vu.lt/VU:ELABAPDB190751850&prefLang=en_USTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.67EF582C |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |